Reich K, Kristensen LE, Smith SD, et al.
Issues - Novembre 2022
Reich K, Kristensen LE, Smith SD, et al.
Coates LC, Mease P, Kronbergs A, et al.
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
Clin Rheumatol. 2022 Oct;41(10):3035-3047Malagoli P, Dapavo P, Pavia G, et al.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)
Dermatol Ther. 2022 Aug;35(8):e15608Gönülal M, Altunay İK, Doğan S, et al.
Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
Dermatol Ther. 2022 Oct 22;e15955Coyne M, Rinaldi A, Brigham K, et al.
Impact of routines and rituals on burden of treatment, patient training, cognitive load, and anxiety in self-injected biologic therapy
Patient Prefer Adherence. 2022 Sep 19;16:2593-2607Jaworecka K, Rzepko M, Marek-Józefowicz L, et al.
The impact of pruritus on the quality of life and sleep disturbances in patients suffering from different clinical variants of psoriasis
J Clin Med. 2022 Sep 22;11(19):5553Chicharro P, Llamas-Velasco M, Armesto S, et al.
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: multicenter study in 384 Spanish patients
Dermatol Ther. 2022 Oct 12;e15929Rathod A, Neema S, Radhakrishnan S, et al.
Palmoplantar plaque psoriasis is associated with diabetes, hypertension, obesity, and metabolic syndrome-a case-control study
Indian Dermatol Online J. 2022 Sep 5;13(5):606-610Mrowietz U, Barker J, Conrad C, et al.
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas, and impaired quality of life: results from the EMBRACE randomized trial
J Eur Acad Dermatol Venereol. 2022 Oct 27Hong JB, Wu PY, Qin A, et al.
Topical tirbanibulin, a dual src kinase and tubulin polymerization inhibitor, for the treatment of plaque-type psoriasis: phase i results
Pharmaceutics. 2022 Oct 11;14(10):2159.Controne I, Scoditti E, Buja A, et al.
Do sleep disorders and western diet influence psoriasis? A scoping review
Nutrients. 2022 Oct 16;14(20):4324Kędra K, Janeczko K, Michalik I, et al.
Sexual dysfunction in women and men with psoriasis: a cross-sectional questionnaire-based study
Medicina (Kaunas). 2022 Oct 13;58(10):1443Ehsan M, Rehman AU, Athar F, et al.
Benvitimod for the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials
Dermatol Ther. 2022 Oct 24;e15957Bhat GH, Guldin S, Khan MS, et al.
Vitamin D status in Psoriasis: impact and clinical correlations
BMC Nutr. 2022 Oct 19;8(1):115McInnes IB, Kato K, Magrey M, et al.
Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study
Rheumatol Ther. 2022 Oct 15;1-18Zema CL, Valdecantos WC, Weiss J, et al.